Open AccessAntibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Author(s) -
Michael D. Swartz,
Stacia M. DeSantis,
Ashraf Yaseen,
Frances A. Brito,
Melissa Valerio-Shewmaker,
Sarah Messiah,
Luis León-Novelo,
Harold W. Kohl,
Cesar L Pinzon-Gomez,
Tianyao Hao,
Shiming Zhang,
Yashar Talebi,
Joy Yoo,
J. Andrew Ross,
Michael O. Gonzalez,
Leqing Wu,
Steven H. Kelder,
Mark Silberman,
Samantha Tuzo,
Stephen J. Pont,
Jennifer A. Shuford,
David Lakey,
Eric Boerwinkle
Publication year - 2022
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiac167
Subject(s) - covid-19 , virology , antibody , coronavirus , betacoronavirus , antibody response , medicine , coronavirus infections , biology , immunology , outbreak , infectious disease (medical specialty) , disease
Understanding the duration of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody Response Survey (Texas CARES) with at least 1 nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n = 4553) with 1 to 3 antibody tests over 11 months (1 October 2020 to 16 September 2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days postinfection, and predicts individuals may remain antibody positive from natural infection beyond 500 days depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not).